A case report of psoriasis exacerbation following COVID-19
- Authors: Khaliullina DR1, Abdrakhmanov RM1
-
Affiliations:
- Kazan State Medical University
- Issue: Vol 102, No 2 (2021)
- Pages: 238-242
- Section: Clinical observations
- URL: https://journals.rcsi.science/kazanmedj/article/view/56551
- DOI: https://doi.org/10.17816/KMJ2021-238
- ID: 56551
Cite item
Open Access
Access granted
Subscription Access
Abstract
The article presents a clinical case of severe exacerbation of psoriasis after a novel coronavirus infection. A 60 years old patient who has recovered from Corona Virus Disease 2019 (COVID-19) was admitted to the Republican Skin and Venereal Disease Dispensary of the Republic of Tatarstan for inpatient treatment with a diagnosis “Large plaque psoriasis involving palms and soles. Progressive stage. Scalp psoriasis. Nail psoriasis”. This was the first time the patient had experienced psoriasis exacerbation of this severity in his medical history. Presumably, exacerbation of psoriasis was due to the use of hydroxychloroquine. The exacerbation of psoriasis during the pandemic outbreak of Coronavirus disease can be explained by the following reasons: use of hydroxychloroquine, excessive inflammatory response to COVID-19, psychological stress, anxiety, depression, the decline in household income, limited outdoor activities. It is necessary to focus attention of physicians to the fact that patients who have suffered from COVID-19 may develop exacerbation of psoriasis.
Full Text
##article.viewOnOriginalSite##About the authors
D R Khaliullina
Kazan State Medical University
Author for correspondence.
Email: dinarakhaliullina796@gmail.com
Russian Federation, Kazan, Russia
R M Abdrakhmanov
Kazan State Medical University
Email: dinarakhaliullina796@gmail.com
Russian Federation, Kazan, Russia
References
- Dermatovenerologiya. Natsional'noe rukovodstvo. Kratkoe izdanie. (Dermatovenereology. National guidelines. Short edition.) Ed. by Y.S. Butova, Y.K. Skripkina, O.L. Ivanova. M.: GEOTAR-Media. 2020; 482–483. (In Russ.)
- Lebwohl M.G., Bachelez H., Barker J., Girolomoni G., Kavanaugh A., Langley R.G., Paul C.F., Puig L., Reich K., van de Kerkhof P.C. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J. Am. Acad. Dermatol. 2014; 70: 871–881. doi: 10.1016/j.jaad.2013.12.018.
- Federal'nye klinicheskie rekomendatsii. Dermatovenerologiya 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. (Federal clinical guidelines. Dermatovenerology 2015. Skin diseases. Sexually transmitted infections.) M.: Delovoy express. 2016; 415–416. (In Russ.)
- Browning J.W., Bolognia J.L., Schaffer J.V., Cerroni L. Dermatology. 4th ed. China: Elsevier. 2018; 2880 p. doi: 10.1111/pde.13439.
- Reken M., Shaller M., Zattler E., Burgdorf V. Atlas po dermatologii. (Dermatology atlas.) 3rd ed. M.: MEDpress-inform. 2018; 408 p. (In Russ.)
- Baniandres-Rodriguez O., Vilar-Alejo J., Rivera R., Carrascosa J.M., Dauden E., Herrera-Acosta E., Sahuquillo-Torralba A., Gomez-Garcia F.J., Nieto-Benito L.M., de la Cueva P., Lopez-Estebaranz J.L., Belinchon I., Ferran Farres M., Alsina M., Fernandez-Freire L.R., Carretero G., Garcia-Donoso C., Ballesca F., Llamas-Velasco M., Herrera-Ceballos E., Botella-Estrada R., Ruiz-Genao D.P., Riera-Monroig J., Descalzo Gallego M.A., Garcia-Doval I.; BIOBADADERM Study Group. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J. Am. Acad. Dermatol. 2021; 84 (2): 513–517. doi: 10.1016/j.jaad.2020.10.046.
- Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19). Versiya 8 (03.09.2020) MZ RF. (The prevention, diagnosis and treatment of the new coronavirus infection 2019-nCoV. Temporary guidelines Ministry of Health of the Russian Federation.) 2020; 10–41. (In Russ.)
- Sachdeva M., Mufti A., Maliyar K., Lytvyn Y., Yeung J. Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment. J. Am. Acad. Dermatol. 2020; 83 (2): 579–586. doi: 10.1016/j.jaad.2020.05.074.
- Said A., Bock S., Lajqi T., Muller G., Weindl G. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J. Immunol. 2014; 193 (12): 6135–6143. doi: 10.4049/jimmunol.1303276.
- Ullah A., Zeb H., Khakwani Z., Murphy F.T. Hydroxychloroquine-induced inverse psoriasis. BMJ Case Rep. 2019; 12 (2): е224619. doi: 10.1136/bcr-2018-224619.
- Kutlu Ö., Metin A. Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol. Ther. 2020; 33:e13509. doi: 10.1111/dth.13509.
- Ozaras R., Berk A., Ucar D.H., Duman H., Kaya F., Mutlu H. Covid-19 and exacerbation of psoriasis. Dermatol. Ther. 2020; 33 (4): е13632. doi: 10.1111/dth.13632.
- Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020; 58: 1021–1028. doi: 10.1515/cclm-2020-0369.
- Kuang Y., Shen M., Wang Q., Xiao Y., Lv C., Luo Y., Zhu W., Chen X. Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey. J. Am. Acad. Dermatol. 2020; 83 (2): 670–672. doi: 10.1016/j.jaad.2020.05.018.
- Kubanov A.A., Bakulev A.L., Kokhan M.M., Olisova O.Y., Samtsov A.V., Sokolovskiy E.V., Khairutdinov V.R., Khobeish M.M. Recommendations Russian Society of Dermatovenerologists and Cosmetologists for systemic treatment of psoriasis during the pandemic COVID-19. Vestnik dermatologii i venerologii. 2020; 96 (2): 9–13. (In Russ.) doi: 10.25208/vdv1129.
- Rossiyskoe obshchestvo dermatovenerologov i kosmetologov. Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh psoriazom. (Federal clinical guidelines for the management of patients with psoriasis.) M. 2015; 9–36. (In Russ.)
Supplementary files
